Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
about
Use of natalizumab in multiple sclerosis: current perspectives.Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity.Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)."No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.Brain Atrophy as a Measure of Neuroprotective Drug Effects in Multiple Sclerosis: Influence of Inflammation.Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling.Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis.Grey matter atrophy is associated with disability increase in natalizumab-treated patients.A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab fingolimod efficacy in multiple sclerosis
P2860
Q31114633-C946FBC0-FAA2-4FDF-B3F2-4C8DADE989C6Q35684256-0426EA2D-BAC0-4D85-B4D8-5BD92F185DE5Q35747637-B4D0B612-1D4F-4FDC-A193-FA98CFAE546FQ36293431-B803A408-5C5F-4A34-B1BB-DD02BCDD1671Q41103337-B016C789-B823-4BD9-B504-B3A1126697BAQ41185260-8C5BA0F4-C75B-4400-9B8E-07498D3D061DQ41490523-33A1062A-FF11-448E-929D-BEC7BB71E912Q41999269-CF6F6391-0E82-41E5-B300-701C2B868A5FQ47878946-1F51D718-637F-4342-A33F-14E9439E9063Q48331558-BB1F224F-3096-4A2A-A3B4-B0EB83724DCAQ48488486-B6F8DC43-3957-4A19-85E1-EC7A6BCCF8CCQ48651177-3E14914C-3CCD-4008-A172-7CEA9DC90782Q48770738-614DD618-4A5B-4789-AD69-1772C167020EQ48821433-F0B86C26-035C-4CC8-A785-121A92EBA784Q48845593-D1E2CA10-6CBF-4DA8-A2D8-25AC4594996EQ50229425-6CE56D48-91AB-480B-B681-E226771A076AQ58564004-88E9D1EE-6B64-4451-9088-5AFDF9BE1984
P2860
Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
@en
Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
@nl
type
label
Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
@en
Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
@nl
prefLabel
Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
@en
Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
@nl
P2093
P2860
P50
P356
P1476
Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
@en
P2093
P2860
P304
P356
10.1177/1352458514556300
P50
P577
2014-11-12T00:00:00Z